Synthetic data, generated through artificial intelligence technologies such as generative adversarial networks and latent ...

In 2015, introduction of a disease staging system offered a framework for benchmarking progression to clinical type 1 ...

The COVID-19 pandemic reminded us of what vaccines can do to prevent life-threatening diseases.1 Respiratory infections such ...

Christy Fischer has never felt lost or sorry for herself during the 18 years since her diagnosis with stage IV lung cancer.

In the early 1990s, a pivotal randomised trial sponsored by the National Institute of Neurological Disorders and Stroke ...

The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

Globally, the prevalence of adolescents experiencing symptoms of anxiety and depression has been rising steeply in the past two decades,1 and diagnoses continue to increase.2 Symptoms of anxiety and ...

I have had Parkinson's [disease] for about 10 years now”, says Ian Temple, an ambassador for and dancer with Dance for ...

The UN has declared November 24 as World Conjoined Twins Day,1 an initiative led by Saudi Arabia to raise global awareness about the medical and societal challenges faced by conjoined twins and their ...

The 2024 Access to Medicine Index shows that some manufacturers are increasingly prioritising LMICs, but broader interest in equitable access is waning. Udani Samarasekera reports.

The long-awaited therapeutic pipeline for Crohn's disease is now coming to fruition, with the emergence of novel drug classes offering hope for our patients. Yet despite increasing options, treatment ...